Enanta Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Enanta Pharmaceuticals, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
Revenue & Gross Profit
Revenue65.3267.6479.2086.1697.07122.47205.20206.63
Cost of Revenue4.590.000.000.000.00-164.11168.460.00
Gross Profit60.7467.6479.2086.1697.07122.47205.200.00
Operating Expenses
Research & Development106.74131.48163.52164.52174.11136.76142.2194.86
Selling, General & Administrative43.9357.8552.8945.4832.5427.3626.2523.44
Operating Expenses146.09189.33216.41210.00206.65164.11168.46118.30
Operating Income-85.35-121.69-137.21-123.84-109.57-41.6436.7488.33
Other Income/Expense
Interest Income9.4814.778.502.742.020.000.004.85
Interest Expense7.6810.94-5.150.000.000.000.000.00
Other Income/Expense1.80-14.77-11.360.080.03-0.15-9.34-0.06
Income
Income Before Tax-83.55-117.79-131.00-122.19-107.58-35.0245.5693.12
Income Tax Expense-1.66-1.742.82-0.43-28.581.15-0.8321.17
Net Income-81.89-116.05-133.82-121.76-79.00-36.1746.3871.96
Net Income - Continuous Operations-81.89-116.05-133.82-121.760.000.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.000.00
EBITDA-70.78-115.45-134.84-120.87-104.25-38.0044.4890.85
EBIT-85.35-117.79-137.21-123.84-107.58-41.6445.5688.33
Depreciation & Amortization5.092.342.372.973.333.643.260.00
Earnings Per Share
Basic EPS-4.00-5.00-6.00-6.00-4.00-2.002.004.00
Diluted EPS-4.00-5.00-6.00-6.00-4.00-2.002.003.00
Basic Shares Outstanding21.340.0220.9720.6020.1719.9419.5819.26
Diluted Shares Outstanding21.340.0220.9720.6020.1719.9420.9720.65